Novocure nabs reimbursement for Optune in Japan

Novocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the anti-cancer drug temozolomide. Get the full story at our sister site, Drug Delivery Business News. The post Novocure nabs reimbursement for Optune in Japan appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat NovoCure Source Type: news